LCM
NVO

LCM Capital Management’s Novo Nordisk NVO Stock Holding History

LCM Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,895
Closed -$269K – 114
2025
Q2 		$269K Sell
3,895
-26
-0.7% -$1.77K 0.14% 87
2025
Q1 		$272K Buy
3,921
+61
+2% +$5.04K 0.16% 80
2024
Q4 		$332K Buy
3,860
+594
+18% +$64.2K 0.19% 67
2024
Q3 		$389K Buy
3,266
+51
+2% +$6.8K 0.22% 58
2024
Q2 		$459K Buy
3,215
+69
+2% +$9.14K 0.29% 50
2024
Q1 		$404K Sell
3,146
-130
-4% -$15.5K 0.26% 53
2023
Q4 		$339K Sell
3,276
-6
-0.2% -$593 0.25% 60
2023
Q3 		$298K Buy
3,282
+198
+6% +$17.4K 0.24% 62
2023
Q2 		$250K Buy
3,084
+208
+7% +$17K 0.2% 73
2023
Q1 		$229K Buy
+2,876
New +$204K 0.2% 78

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LCM Capital Management's NVO Position: Q3 2025 in Review

LCM Capital Management sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 3,895 shares — an estimated $269K sold.

LCM Capital Management first reported a position in NVO in Q1 2023 and held it in 10 quarters. The position peaked at $459K in Q2 2024. 1,396 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • LCM Capital Management reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • LCM Capital Management sold 3,895 Novo Nordisk shares in Q3 2025, an estimated $269K.
  • LCM Capital Management first reported a position in Novo Nordisk in Q1 2023 and held it in 10 quarters.
  • LCM Capital Management's Novo Nordisk position peaked at $459K in Q2 2024.
  • 1,396 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on LCM Capital Management's 13F filing for Q3 2025, filed 28 Oct 2025.